Pfizer opts into LianBio's RSV drug sisunatovir rights in China & Singapore; $20M upfront, up to $135M milestones

LianBio

$20M upfront payment from previously restricted cash paid by Pfizer in 2020 under the existing strategic collaboration.
Up to $135M in potential development and commercial milestone payments plus tiered low single-digit percent of net sales.
Pfizer assumes all development/commercial costs in the region and releases LianBio from its royalty and milestone obligations to ReViral.
LianBio expects the transaction to extend cash runway through end of 2024.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

LianBio entered into Commercial Agreement with Pfizer Inc. and ReViral Ltd. valued at $20 million upfront payment, up to $135 million in potential milestones (effective 2022-12-16).

Action: entry
Agreement: asset purchase
Counterparty: Pfizer Inc. and ReViral Ltd.
Value: $20 million upfront payment, up to $135 million in potential milestones
Effective: 2022-12-16

Exact text from the filing

On December 16, 2022, LianBio Development HK Limited and LianBio Respiratory Limited, each a wholly-owned subsidiary of LianBio (the “Company,” and collectively with LianBio Development HK Limited and LianBio Respiratory Limited, “LianBio”), Pfizer Inc. (“Pfizer”) and ReViral Ltd. (“ReViral,” now a wholly-owned subsidiary of Pfizer) entered into a commercial agreement (the “Commercial Agreement”) with respect to sisunatovir (a fusion inhibitor product for treatment of respiratory syncytial virus (or RSV)) as the first Opted-in Product under the Strategic Collaboration Agreement dated November 17, 2020 by and between the Company and Pfizer (the “Collaboration Agreement”).

View on SEC.gov

148 material agreements filed in the last 30 days. Browse all material agreements →

LianBio filing history →

Source: SEC EDGAR

accession 0001831283-22-000082

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.